Journal
BLOOD ADVANCES
Volume 6, Issue 1, Pages 339-357Publisher
ELSEVIER
DOI: 10.1182/bloodadvances.2021004916
Keywords
-
Categories
Funding
- National Cancer Institute [U24CA076518, R01CA215134]
- National Heart, Lung, and Blood Institute [R01HL130388, UG1HL06924]
- National Insti-tute of Allergy and Infectious Diseases [R01AI128775]
- Health Resources and Services Administration [HHSH250201700006C, HHSH250201700007C]
- Office of Naval Research [N00014-20-1-2705, N00014-20-1-2832]
- Biomedical Advanced Research and Development Authority
- Actinium Pharmaceuticals
- Adienne
- Allovir
- Amgen
- Angiocrine Bio-science
- Astellas Pharma
- bluebird bio
- Boston Children's Hospital
- Bristol Myers Squibb
- Be the Match Foundation
- Celgene
- CSL Behring
- CytoSen Therapeutics
- Daiichi Sankyo
- Dana-Farber Cancer Institute
- ExcellThera
- Fate Therapeutics
- Gamida-Cell
- Genentech
- Incyte
- Janssen/Johnson Johnson
- Jazz Pharmaceuticals
- Kiadis Pharma
- Kite Pharma
- Kyowa Kirin
- Legend Biotech
- Magenta Thera-peutics
- Medical College of Wisconsin
- Merck Sharp Dohme
- Millen-nium Pharmaceuticals
- Miltenyi Biotec
- National Marrow Donor Program
- Novartis Pharmaceuticals
- Omeros
- OncoImmune
- Orca Bio-systems
- Pfizer
- Pharmacyclics
- Sanofi Genzyme
- St. Baldrick's Foun-dation
- Stanford University
- Stemcyte
- Takeda Oncology
- Takeda Pharma
- Vor Biopharma
- Xenikos
Ask authors/readers for more resources
This study compared the outcomes of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) with other HCT approaches for acute lymphoblastic leukemia (ALL) patients. The results showed that haploidentical HCT using PTCy had similar overall survival (OS) but lower incidence of chronic graft-versus-host disease (cGVHD) compared to traditional matched sibling and unrelated donor HCT methods, making it a preferred alternative donor option for ALL patients in complete remission.
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLAmatched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P <_ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P <_ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (<_18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available